Integration of VR and AR Dementia Prevention Health Education Progrom for Older Adults With Mild Cognitive Impairment
Launched by NATIONAL TAIWAN NORMAL UNIVERSITY · Mar 15, 2025
Trial Information
Current as of May 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is a randomized controlled trial (RCT) aimed at evaluating the effectiveness of a Virtual Reality (VR)-based cognitive health education program for older adults in Taiwan who show signs of mild cognitive impairment (MCI). The research seeks to determine whether VR-enhanced dementia prevention education increases dementia-related knowledge, health literacy, self-efficacy, and acceptance of dementia compared to a control group receiving standard health education without VR exposure and intervention.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 65 years and older.
- • AD-8 score of 2 or higher, indicating possible cognitive impairment.
- • Ability to understand and follow basic instructions in Mandarin or Taiwanese.
- • Capacity to provide informed consent or have a legally authorized representative to provide consent.
- • Ability to tolerate and interact with VR equipment (e.g., wearing a VR headset, using hand controllers).
- Exclusion Criteria:
- • Diagnosed with moderate to severe dementia (i.e., unable to follow basic instructions).
- • Presence of severe visual, auditory, or motor impairments that hinder interaction with VR devices.
- • Diagnosed with severe psychiatric disorders (e.g., schizophrenia, major depressive disorder).
- • Unable to communicate effectively in Mandarin or Taiwanese.
About National Taiwan Normal University
National Taiwan Normal University (NTNU) is a prestigious institution dedicated to advancing education and research across various disciplines, including health sciences. As a clinical trial sponsor, NTNU leverages its academic expertise and innovative methodologies to investigate and develop novel therapeutic interventions. The university fosters collaboration between researchers, healthcare professionals, and industry partners to ensure rigorous study design, ethical standards, and comprehensive data analysis. By prioritizing scientific excellence and community health, NTNU aims to contribute significantly to the advancement of medical knowledge and the improvement of patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported